Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

The XPO1-FOXC1-HOX Functional Axis Opens New Therapeutic Avenues to Treat DEK-NUP214 AML Patients

Blood (2023) 142 (Supplement 1): 4302.

https://doi.org/10.1182/blood-2023-174891

Published: 2023

Journal Articles

Ex Vivo Venetoclax Sensitivity Testing Predicts Response and Overall Survival in De Novo and s/R/R AML Patients Treated with Azacitidine and Venetoclax

Blood (2022) 140 (Supplement 1): 2020–2022.

https://doi.org/10.1182/blood-2022-159391

Published: 2022

Journal Articles

Deep Multi-Omics Profiling in Cytogenetically Poor-Risk AML

Blood (2022) 140 (Supplement 1): 1030–1032.

https://doi.org/10.1182/blood-2022-159069

Published: 2022

Journal Articles

Integration of Deep Multi-Omics Profiling Veals New Insights into the Biology of Poor-Risk Acute Myeloid Leukemia

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-141345

Published: 2020

Journal Articles

Associations between Microrna Expression, Disease Progression and Ex Vivo Drug Response in Multiple Myeloma

Romika Kumari, PhD, Ashwini Kumar, MRes, Alun Parsons, Minna Suvela, MSC, Juha Lievonen, MD, Raija Helena Silvennoinen, MD PhD, Pekka Anttila, MD, Caroline A Heckman, PhD

Blood (2019) 134 (Supplement_1): 3069.

https://doi.org/10.1182/blood-2019-128181

Published: 2019

Journal Articles

Combined Targeting of BET Family Proteins and BCL2 Is Synergistic in Acute Myeloid Leukemia Cells Overexpressing S100A8 and S100A9

Riikka Karjalainen, Minxia Liu, Ashwini Kumar, MRes, Alun Parsons, Liye He, Dishaben Rameshbhai Malani, MSc, Mika Kontro, MD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2018) 132 (Supplement 1): 2634.

https://doi.org/10.1182/blood-2018-99-118890

Published: 2018

Journal Articles

Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types

Muntasir M Majumder, MSc, BPharm, Maija Leppä, MSc(Tech), Monica Hellesoy, PhD, Paul Dowling, BSc, PhD, Alina Malyutina, Despina Bazou, BSc, MSc, PhD, Emma Irene Andersson, MSc, Alun Parsons, Jing Tang, PhD, Olli Kallioniemi, MD PhD, Satu Mustjoki, MDPhD, Peter O'Gorman, MD PhD FRCP, FRCPath, Krister Wennerberg, PhD, Kimmo Porkka, MD PhD, Bjorn Gjertsen, MD PhD, Caroline A Heckman, PhD

Blood (2018) 132 (Supplement 1): 264.

https://doi.org/10.1182/blood-2018-99-118242

Published: 2018

Journal Articles

Midostaurin Shows Efficacy in Refractory Multiple Myeloma with TP53 Mutation and Elevated Expression of NTRK1, NTRK3 and AURKA

Muntasir M Majumder, MSc, BPharm, David Tamborero, PhD, Pekka Anttila, Raija Helena Silvennoinen, MD, Samuli Eldfors, MSc, Juha Lievonen, Ashwini Kumar, MRes, Alun Parsons, Minna Suvela, MSC, Esa Jantunen, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2017) 130 (Supplement 1): 4412.

https://doi.org/10.1182/blood.V130.Suppl_1.4412.4412

Published: 2017

Journal Articles

Elevated Expression of the S100A8/S100A9 Complex in AML Correlates with Reduced Sensitivity to the BCL2 Inhibitor Venetoclax

Riikka Karjalainen, Minxia Liu, Ashwini Kumar, MRes, Alun Parsons, Mika Kontro, MD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2017) 130 (Supplement 1): 298.

https://doi.org/10.1182/blood.V130.Suppl_1.298.298

Published: 2017

Journal Articles

JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML

Blood (2017) 130 (6): 789–802.

https://doi.org/10.1182/blood-2016-02-699363

Published: 2017

Includes: Supplemental data

Journal Articles

Identification of Optimized Compound Combinations for the Treatment of NUP98-NSD1+ AML

Jarno Kivioja, MSc, Angeliki Thanasopoulou, PhD, Mika Kontro, MD, Bhagwan Yadav, MSc, Muntasir Mamun Majumder, MSc, Heikki Kuusanmäki, MSc, Alun Parsons, MSc, Kimmo Porkka, MD PhD, Juerg Schwaller, MD, Caroline A Heckman, PhD

Blood (2016) 128 (22): 4711.

https://doi.org/10.1182/blood.V128.22.4711.4711

Published: 2016

Journal Articles

DNA Damage Repair Pathway Alterations in Multiple Myeloma Predict Poor Prognosis, but Correlate with Sensitivity to IGF1R-PI3K-mTOR and HDAC Inhibitors

Muntasir M Majumder, MSc, MPharm, David Tamborero, PhD, Pekka Anttila, MD, Raija Silvennoinen, MD, Samuli Eldfors, MSc, Ashwini Kumar, MSc, Juha Lievonen, MD, Alun Parsons, MSc, Minna Suvela, Esa Jantunen, MD PhD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2016) 128 (22): 198.

https://doi.org/10.1182/blood.V128.22.198.198

Published: 2016

Journal Articles

Targeting of JAK/STAT Signaling to Reverse Stroma-Induced Cytoprotection Against BCL2 Antagonist Venetoclax in Acute Myeloid Leukemia

Riikka Karjalainen, Mihaela Popa, Dr, Minxia Liu, Mika Kontro, Mireia Mayoral Safont, Alun Parsons, MSc, Kimmo Porkka, MD PhD, Krister Wennerberg, Emmet McCormack, Dr, PhD, Bjørn T. Gjertsen, Caroline A Heckman, PhD

Blood (2016) 128 (22): 32.

https://doi.org/10.1182/blood.V128.22.32.32

Published: 2016

Journal Articles

BCL2-Inhibitors Target a Major Group of Newly-Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia Ex Vivo

Mika Kontro, MD, Samuli Eldfors, MSc, Muntasir Mamun Majumder, MSc,MPharm, Alun Parsons, MSc, Tea Pemovska, MSc, Olli Kallioniemi, MD PhD, Krister Wennerberg, PhD, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD

Blood (2015) 126 (23): 2462.

https://doi.org/10.1182/blood.V126.23.2462.2462

Published: 2015

Journal Articles

Stratification of Multiple Myeloma Patients Based on Ex Vivo Drug Sensitivity and Identification of New Treatments for Patients with High-Risk Relapsed/Refractory Disease

Muntasir Mamun Majumder, MSc,MPharm, Raija Silvennoinen, MD, Pekka Anttila, MD, David Tamborero, PhD, Samuli Eldfors, MSc, Juha Lievonen, MD, Riikka J Karjalainen, Heikki Kuusanmäki, MSc, Alun Parsons, Minna Suvela, Kimmo Porkka, MD PhD, Caroline Heckman

Blood (2015) 126 (23): 3006.

https://doi.org/10.1182/blood.V126.23.3006.3006

Published: 2015

Journal Articles

JAK1/2 and BCL2 Inhibitors Synergize to Counter-Act Bone Marrow Stromal Cell-Induced Protection of AML

Riikka Karjalalainen, Tea Pemovska, Muntasir Mamun Majumder, Bhagwan Yadav, Jing Tang, Mika Kontro, Bjørn Gjertsen, MD PhD, Alun Parsons, Minna Suvela, Kimmo Porkka, Tero Aittokallio, Olli Kallioniemi, Krister Wennerberg, Jonathan Knowles, Caroline Heckman

Blood (2015) 126 (23): 867.

https://doi.org/10.1182/blood.V126.23.867.867

Published: 2015

Journal Articles

Identification of Dual PI3K/mTOR and BCL2 Inhibitors for the Treatment of High Risk Multiple Myeloma

Raija Silvennoinen, MD, Muntasir Mamun Majumder, MSc,BPharm, David Tamborero, PhD, Pekka Anttila, MD, Samuli Eldfors, MSc, Riikka Karjalainen, MSc, Heikki Kuusanmäki, MSc, Juha Lievonen, MD, Alun Parsons, MSc, Minna Suvela, Marjaana Säily, MDPhD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2014) 124 (21): 646.

https://doi.org/10.1182/blood.V124.21.646.646

Published: 2014

Journal Articles

Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma

Muntasir Mamun Majumder, MSc,BPharm, Raija Silvennoinen, MD, Pekka Antilla, David Tamborero, Samuli Eldfors, MSc, Riikka Karjalainen, MSc, Heikki Kuusanmäki, MSc, Juha Lievonen, MD, Alun Parsons, MSc, Minna Suvela, Marjanna Säily, Bhagwan Yadav, MSc, Krister Wennerberg, PhD, Olli Kallioniemi, MD PhD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2014) 124 (21): 2046.

https://doi.org/10.1182/blood.V124.21.2046.2046

Published: 2014

Journal Articles

Landscape of Driver Lesions in Multiple Myeloma and Consequences for Targeted Drug Response

David Tamborero, PhD, Muntasir Mamun Majumder, MSc,BPharm, Raija Silvennoinen, MD, Samuli Eldfors, MSc, Pekka Anttila, MD, Juha Lievonen, MD, Alun Parsons, MSc, Minna Suvela, BSc, Marjanna Säily, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2014) 124 (21): 3351.

https://doi.org/10.1182/blood.V124.21.3351.3351

Published: 2014

Journal Articles

Stroma-Derived Factors Significantly Impact the Drug Response Profiles of Patient-Derived Primary AML Cells: Implications for Drug Sensitivity Testing

Riikka Karjalainen, MSc, Tea Pemovska, MSc, Muntasir Mamun Majumder, MSc, David Tamborero, PhD, Bhagwan Yadav, MSc, Mika Kontro, MD, Bjørn Gjertsen, MD PhD, Alun Parsons, MSc, Minna Suvela, BSc, Tero Aittokallio, PhD, Kimmo Porkka, MD PhD, Olli Kallioniemi, MD PhD, Krister Wennerberg, PhD, Caroline A Heckman, PhD

Blood (2014) 124 (21): 3505.

https://doi.org/10.1182/blood.V124.21.3505.3505

Published: 2014

NARROW

The XPO1-FOXC1-HOX Functional Axis Opens New Therapeutic Avenues to Treat DEK-NUP214 AML Patients

Ex Vivo Venetoclax Sensitivity Testing Predicts Response and Overall Survival in De Novo and s/R/R AML Patients Treated with Azacitidine and Venetoclax

Deep Multi-Omics Profiling in Cytogenetically Poor-Risk AML

Integration of Deep Multi-Omics Profiling Veals New Insights into the Biology of Poor-Risk Acute Myeloid Leukemia

Associations between Microrna Expression, Disease Progression and Ex Vivo Drug Response in Multiple Myeloma

Combined Targeting of BET Family Proteins and BCL2 Is Synergistic in Acute Myeloid Leukemia Cells Overexpressing S100A8 and S100A9

Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types

Midostaurin Shows Efficacy in Refractory Multiple Myeloma with TP53 Mutation and Elevated Expression of NTRK1, NTRK3 and AURKA

Elevated Expression of the S100A8/S100A9 Complex in AML Correlates with Reduced Sensitivity to the BCL2 Inhibitor Venetoclax

JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML

Identification of Optimized Compound Combinations for the Treatment of NUP98-NSD1+ AML

DNA Damage Repair Pathway Alterations in Multiple Myeloma Predict Poor Prognosis, but Correlate with Sensitivity to IGF1R-PI3K-mTOR and HDAC Inhibitors

Targeting of JAK/STAT Signaling to Reverse Stroma-Induced Cytoprotection Against BCL2 Antagonist Venetoclax in Acute Myeloid Leukemia

BCL2-Inhibitors Target a Major Group of Newly-Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia Ex Vivo

Stratification of Multiple Myeloma Patients Based on Ex Vivo Drug Sensitivity and Identification of New Treatments for Patients with High-Risk Relapsed/Refractory Disease

JAK1/2 and BCL2 Inhibitors Synergize to Counter-Act Bone Marrow Stromal Cell-Induced Protection of AML

Identification of Dual PI3K/mTOR and BCL2 Inhibitors for the Treatment of High Risk Multiple Myeloma

Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma

Landscape of Driver Lesions in Multiple Myeloma and Consequences for Targeted Drug Response

Stroma-Derived Factors Significantly Impact the Drug Response Profiles of Patient-Derived Primary AML Cells: Implications for Drug Sensitivity Testing

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only